Blog
RSS FeedPosted by Michael Wonder on 10 Nov 2018
NICE says no to expanding use of AstraZeneca's’ Lynparza
9 November 2018 - NICE has ruled against expanding use of AstraZeneca’s Lynparza to a wider patient population with ovarian ...
Posted by Michael Wonder on 09 Nov 2018
Lenvima backed for NHS use to treat liver cancer
9 November 2018 - NICE has issued draft guidelines backing use of Eisai/MSD’s Lenvima on the NHS in England and ...
Posted by Michael Wonder on 09 Nov 2018
NICE nod for Jazz’ AML chemo
8 November 2018 - Jazz Pharmaceuticals’ chemotherapy Vyxeos has won the backing of NICE for routine use on the NHS ...
Posted by Michael Wonder on 07 Nov 2018
NHS England in legal battle with American firm over medicine procurement
7 November 2018 - An American pharmaceutical company has launched a legal challenge against NHS England over a procurement process ...
Posted by Michael Wonder on 31 Oct 2018
NICE to retire guidance app
31 October 2018 - Following improved access and optimisation of the website, the NICE guidance app will no longer be available ...
Posted by Michael Wonder on 29 Oct 2018
NICE turns down hyperkalaemia therapies
29 October 2018 - Preliminary guidelines released by the NICE do not recommend NHS funding for hyperkalaemia treatments Lokelma and ...
Posted by Michael Wonder on 26 Oct 2018
AbbVie’s CLL drug Venclyxto too expensive for NHS, says NICE
26 October 2018 - NICE has said AbbVie’s Venclyxto (venetoclax), in combination with development partner Roche’s MabThera/Rituxan (rituximab), is not ...
Posted by Michael Wonder on 24 Oct 2018
MS and cholesterol drugs picked for new UK rapid uptake push
24 October 2018 - Accelerated Access Collaborative aims to break down barriers to faster uptake ...
Posted by Michael Wonder on 20 Oct 2018
Some European countries decide to cover cancer drugs much faster than others
19 October 2018 - Some European countries take more than twice as long as others to decide whether to provide ...
Posted by Michael Wonder on 19 Oct 2018
NICE rejects Lilly’s breast cancer drug Verzenios
19 October 2018 - As it stands Eli Lilly’s Verzenios will not be routinely funded on the NHS for breast ...
Posted by Michael Wonder on 18 Oct 2018
NHS green light for Novartis skin cancer combo
18 October 2018 - The NHS now has three months to ensure that Novartis’ combination therapy dabrafenib/trametinib is routinely available ...
Posted by Michael Wonder on 16 Oct 2018
New checks to crack down on free prescription fraud
14 October 2018 - Patients claiming free prescriptions in England face checks before medicine is issued in an effort to ...
Posted by Michael Wonder on 11 Oct 2018
ABPI tells MPs Brexit deal on medicines regulation ‘urgently needed’
11 October 2018 - Pharmaceutical companies “are doing everything in their power” to minimise disruption to the supply of medicines ...
Posted by Michael Wonder on 10 Oct 2018
XLH patients to get routine access to first new therapy in 30 years
10 October 2018 - For the first time in more than 30 years children and young adults in England and ...
Posted by Michael Wonder on 08 Oct 2018
NICE expands backing for Pfizer’s Mylotarg
8 October 2018 - NICE is recommending Mylotarg for previously untreated, de novo, CD33-positive acute myeloid leukaemia in combination with ...